Polpharma Biologics Announces EMA Acceptance for Proposed Biosimilar Natalizumab (Tysabri)
European Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS).